# Chemed Corp: Form 10-Q for the period ended Mar 31, 2026

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2026-04-28
- Accepted by EDGAR: Apr 28, 2026, 09:00 ET
- Period: 2026-03-31
- Accession: 0000019584-26-000012
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000001958426000012/che-20260331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000001958426000012/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-01-01 to 2026-03-31 | $657.5m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2026-01-01 to 2026-03-31 | $441.7m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2026-01-01 to 2026-03-31 | $114.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2026-01-01 to 2026-03-31 | $84.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2026-01-01 to 2026-03-31 | $512.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2026-01-01 to 2026-03-31 | $22.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-01-01 to 2026-03-31 | $66.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-01-01 to 2026-03-31 | $4.84 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-01-01 to 2026-03-31 | $4.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-01-01 to 2026-03-31 | 13,690,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2026-01-01 to 2026-03-31 | $88.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2026-01-01 to 2026-03-31 | $17.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2026-01-01 to 2026-03-31 | $8.2m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2026-01-01 to 2026-03-31 | $190.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2026-03-31 | $16.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2026-03-31 | $274.1m | us-gaap:AssetsCurrent |
| Total assets | at 2026-03-31 | $1.54bn | us-gaap:Assets |
| Current liabilities | at 2026-03-31 | $321.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-03-31 | $687.8m | us-gaap:Liabilities |
| Long-term debt | at 2026-03-31 | $91.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2026-03-31 | $848.0m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2026-03-31 | 13,274,104 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 28,257 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, excavation, water restoration, and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world. We continue to monitor macroeconomic trends and uncertainties such as inflation, the effects of recently implemented tariffs, and the potential imposition of modified or additional tariffs, as well as the impact of the war with Iran on fuel prices, which may have adverse effects on net sales and profitability. Based on preliminary analysis of the potential effects of the announced tariffs and these other factors, we do not expect a material negative effect on our net sales or profitability for the remainder of fiscal year 2026. However, we are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts for fiscal year 2027 planning. Economic pressures including the challenges of high inflation and the effects of increased tariffs and the impact of the war with Iran may negatively affect our net sales and profitability in the future.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| Service revenues and sales | **$657,513** | $646,943 |
| Net income | **$66,302** | $71,757 |
| Diluted EPS | **$4.84** | $4.86 |
| Adjusted net income | **$77,383** | $83,074 |
| Adjusted diluted EPS | **$5.65** | $5.63 |
| Adjusted EBITDA | **$116,257** | $121,692 |
| Adjusted EBITDA as a % of revenue | **17.7%** | 18.8% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 28-29.

For the three months ended March 31, 2026, the increase in consolidated service revenues and sales was driven by a 3.1% increase at VITAS offset by a 0.9% decrease at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of 2.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 120-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes decreased revenue growth by 47-basis points.

The decline in service revenues at Roto-Rooter was driven by a 1.9% decrease in commercial revenue and a 1.5% decrease in residential revenue.

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2025 to March 31, 2026 include the following:

A $32.9 million increase in accounts receivable due to the timing of payments. Other significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $62.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

A $20.5 million increase in goodwill due to the two acquisitions at Roto-Rooter.

A $23.3 million increase in income taxes payable due to timing of payments.

A $91.2 million increase in long-term debt due primarily to the acquisitions and stock repurchases.

A $201.1 million increase in treasury stock due to stock repurchases.

Net cash provided by operating activities increased $55.5 million from March 31, 2025 to March 31, 2026. See the Unaudited Consolidated Statements of Cash Flow on page 5 for the detail components making up the change.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

### Commitments and Contingencies

On April 10, 2026, we replaced the Prior Credit Agreement with a sixth amended and restated Credit Agreement. Terms of the Credit Agreement consist of a five-year $450.0 million revolving credit facility including $100.0 million for letters of credit. The interest on this Credit Agreement has a floating interest rate that is generally the secured overnight financing rate (“SOFR”) plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2026, the interest rate is SOFR plus 100 basis points. The Credit Agreement includes an expansion feature that provides the Company the opportunity to increase its revolver by an additional $250.0 million.

We have issued $45.5 million in standby letters of credit as of March 31, 2026 under the Prior Credit Agreement, which has continued under the Credit Agreement mainly for insurance purposes. Issued letters of credit reduce our available credit under the Credit Agreement. As of March 31, 2026, we have approximately $313.3 million of unused lines of credit available and are eligible to be drawn down under the Prior Credit Agreement. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Collectively, the terms of the Credit Agreement require us to meet various financial covenants, to be tested quarterly. We were in compliance with all financial and other debt covenants as of March 31, 2026 under the Prior Credit Agreement and anticipate remaining in compliance under the Credit Agreement throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

### Results of Operations

### Three months ended March 31, 2026 versus 2025 - Consolidated Results

Our service revenues and sales for the first quarter of 2026 increased 1.6% versus services and sales revenues for the first quarter of 2025. Of this increase, a $12.6 million increase was attributable to VITAS, offset by a $2.0 million decrease at Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

| VITAS | Three months ended March 31, 2026 | 2025 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **$371,091** | $351,566 | 5.6 |
| General inpatient | **35,925** | 34,022 | 5.6 |
| Continuous care | **18,133** | 24,637 | (26.4) |
| Other | **5,578** | 5,344 | 4.4 |
| Subtotal | **430,727** | 415,569 | 3.6 |
| Medicare cap adjustment | **(2,375)** | (2,325) | (2.2) |
| Room and board - net | **(3,257)** | (3,525) | 7.6 |
| Implicit price concessions | **(5,077)** | (2,319) | (118.9) |
| Net revenue | **$420,018** | $407,400 | 3.1 |
| Roto-Rooter |  |  |  |
| Drain cleaning | **$59,735** | $59,542 | 0.3 |
| Plumbing | **49,584** | 46,059 | 7.7 |
| Excavation | **63,510** | 64,239 | (1.1) |
| Other | **229** | 186 | 23.1 |
| Subtotal - short term core | **173,058** | 170,026 | 1.8 |
| Water restoration | **47,848** | 54,163 | (11.7) |
| Independent contractors | **17,765** | 18,362 | (3.3) |
| Outside franchisee fees | **1,521** | 1,424 | 6.8 |
| Other | **5,089** | 4,895 | 4.0 |
| Gross revenue | **245,281** | 248,870 | (1.4) |
| Implicit price concessions | **(7,786)** | (9,327) | 16.5 |
| Net revenue | **237,495** | 239,543 | (0.9) |
| Total Revenues | $657,513 | $646,943 | 1.6 |

Days of care at VITAS during the quarters were as follows:

|  | Three months ended March 31, 2026 | 2025 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **1,691,619** | 1,632,569 | 3.6 |
| Nursing home | **294,818** | 307,108 | (4.0) |
| Respite | **10,875** | 9,995 | 8.8 |
| Subtotal routine homecare and respite | **1,997,312** | 1,949,672 | 2.4 |
| General inpatient | **30,474** | 29,704 | 2.6 |
| Continuous care | **17,288** | 22,620 | (23.6) |
| Total days of care | **2,045,074** | 2,001,996 | 2.2 |

The increase in service revenues at VITAS is comprised primarily of 2.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 120-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes decreased revenue growth by 47-basis points.

The increase in plumbing revenues for the first quarter of 2026 versus 2025 is attributable to a 14.1% increase in price and service mix shift offset by a 6.4% decrease in job count. The increase in drain cleaning revenues for the first quarter of 2026 versus 2025 is attributable to a 12.3% increase in price and service mix offset by a 12.0% decrease in job count. Excavation revenues decreased

1.1%, water restoration revenues decreased 11.7%, and contractors operations decreased 3.3%. Implicit price concessions and credit memos decreased 16.5% mainly related to the water restoration business.

The consolidated gross margin was 32.8% in the first quarter of 2026 as compared with 33.5% in the first quarter of 2025. On a segment basis, VITAS’ gross margin was 22.5% in the first quarter of 2026 as compared with 23.2% in the first quarter of 2025. The decline is related to an increase in variable patient care expenses in the first quarter of 2026 compared to the first quarter of 2025. The Roto-Rooter segment’s gross margin was 51.0% for the first quarter of 2026 which was essentially flat with the first quarter of 2025.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

|  | Three months ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | **$108,931** | $103,760 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | **3,885** | (830) |
| Long-term incentive compensation | **1,505** | 2,657 |
| Total SG&A expenses | **$114,321** | $105,587 |

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2026 were up 5.0% when compared to the first quarter of 2025. $3.9 million of this increase was the result of increased advertising at Roto-Rooter in the first quarter of 2026 compared to the first quarter of 2025.

Other income – net comprise (in thousands):

|  | Three months ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| Market value adjustment on assets held in deferred compensation trusts | **$3,885** | $(830) |
| Interest income | **890** | 2,076 |
| Other | **(1)** | (1) |
| Total other income - net | **$4,774** | $1,245 |

We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. Chemed invests excess cash in money market funds holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

|  | Three months ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| Income tax provision calculated at the statutory federal rate | **$18,656** | $20,092 |
| State and local income taxes, less federal income tax effect | **2,716** | 4,187 |
| Nondeductible expenses: |  |  |
| Stock compensation tax expense/(benefit) | **56** | (463) |
| Other--net | **1,110** | 101 |
| Income tax provision | **$22,538** | $23,917 |
| Effective tax rate | 25.4% | 25.0% |

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

| Roto-Rooter | Three months ended March 31, 2026 $$ | 2025 |
| --- | ---: | ---: |
| Amortization of reacquired franchise agreements | **(1,804)** | (1,806) |
| Acquisition expense | **(128)** | - |
| Corporate |  |  |
| Stock option expense | **(7,750)** | (7,621) |
| Long-term incentive compensation | **(1,343)** | (2,353) |
| Excess tax (expense)/benefit on stock compensation | **(56)** | 463 |
| Total | **$(11,081)** | $(11,317) |

### Three months ended March 31, 2026 versus 2025 - Segment Results

Net income/(loss) for the first quarter of 2026 versus the first quarter of 2025 by segment (in thousands):

|  | Three months ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| VITAS | **$52,207** | $50,030 |
| Roto-Rooter | **35,784** | 39,944 |
| Corporate | **(21,689)** | (18,217) |
|  | **$66,302** | $71,757 |

After-tax earnings as a percent of revenue at VITAS in the first quarter of 2026 was 12.4% as compared to 12.3% in the first quarter of 2025.

Roto-Rooter’s net income was negatively impacted in the first quarter of 2026 compared to the first quarter of 2025 due mainly to an increase in marketing expenses. Roto-Rooter’s after-tax earnings as a percent of revenue in the first quarter of 2026 was 15.1%, as compared to 16.7% in the first quarter of 2025.

After-tax Corporate expenses for the first quarter of 2026 increased 19.1% when compared to the first quarter in 2025 due primarily to a $1.5 million increase in intercompany interest expense, a lower tax benefit related to reduced stock option exercises and a $1.2 million decrease in interest income offset by an $881,000 decrease in stock-based compensation.

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2026*

*(in thousands)(unaudited)*

| 2026 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Service revenues and sales** | **$420,018** | **$237,495** | **$-** | **$657,513** |
| **Cost of services provided and goods sold** | **325,467** | **116,282** | **-** | **441,749** |
| **Selling, general and administrative expenses** | **26,109** | **67,929** | **20,283** | **114,321** |
| **Depreciation** | **5,912** | **8,379** | **12** | **14,303** |
| **Amortization** | **26** | **2,544** | **-** | **2,570** |
| **Other operating (income)/expense** | **52** | **(60)** | **-** | **(8)** |
| **Total costs and expenses** | **357,566** | **195,074** | **20,295** | **572,935** |
| **Income/(loss) from operations** | **62,452** | **42,421** | **(20,295)** | **84,578** |
| **Interest expense** | **(50)** | **(136)** | **(326)** | **(512)** |
| **Intercompany interest income/(expense)** | **6,238** | **4,512** | **(10,750)** | **-** |
| **Other income—net** | **95** | **15** | **4,664** | **4,774** |
| **Income/(expense) before income taxes** | **68,735** | **46,812** | **(26,707)** | **88,840** |
| **Income taxes** | **(16,528)** | **(11,028)** | **5,018** | **(22,538)** |
| **Net income/(loss)** | **$52,207** | **$35,784** | **$(21,689)** | **$66,302** |
| **(a) The following amounts are included in net income (in thousands):** |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Pretax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(9,249)** | **$(9,249)** |
| **Amortization of reacquired franchise agreements** | **-** | **(2,352)** | **-** | **(2,352)** |
| **Long-term incentive compensation** | **-** | **-** | **(1,505)** | **(1,505)** |
| **Acquisition expense** | **-** | **(167)** | **-** | **(167)** |
| **Total** | **$-** | **$(2,519)** | **$(10,754)** | **$(13,273)** |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **After-tax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(7,750)** | **$(7,750)** |
| **Amortization of reacquired franchise agreements** | **-** | **(1,804)** | **-** | **(1,804)** |
| **Long-term incentive compensation** | **-** | **-** | **(1,343)** | **(1,343)** |
| **Acquisition expense** | **-** | **(128)** | **-** | **(128)** |
| **Excess tax expense on stock compensation** | **-** | **-** | **(56)** | **(56)** |
| **Total** | **$-** | **$(1,932)** | **$(9,149)** | **$(11,081)** |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED MARCH 31, 2025*

*(in thousands)(unaudited)*

| 2025 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $407,400 | $239,543 | $- | $646,943 |
| Cost of services provided and goods sold | 312,807 | 117,723 | - | 430,530 |
| Selling, general and administrative expenses | 26,538 | 62,649 | 16,400 | 105,587 |
| Depreciation | 5,196 | 8,237 | 12 | 13,445 |
| Amortization | 26 | 2,546 | - | 2,572 |
| Other operating expense/(income) | 64 | (13) | - | 51 |
| Total costs and expenses | 344,631 | 191,142 | 16,412 | 552,185 |
| Income/(loss) from operations | 62,769 | 48,401 | (16,412) | 94,758 |
| Interest expense | (48) | (132) | (149) | (329) |
| Intercompany interest income/(expense) | 5,296 | 3,930 | (9,226) | - |
| Other income—net | 48 | 10 | 1,187 | 1,245 |
| Income/(expense) before income taxes | 68,065 | 52,209 | (24,600) | 95,674 |
| Income taxes | (18,035) | (12,265) | 6,383 | (23,917) |
| Net income/(loss) | $50,030 | $39,944 | $(18,217) | $71,757 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(9,091) | $(9,091) |
| Long-term incentive compensation | - | - | (2,657) | (2,657) |
| Amortization of reacquired franchise agreements | - | (2,352) | - | (2,352) |
| Total | $- | $(2,352) | $(11,748) | $(14,100) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Stock option expense | $- | $- | $(7,621) | $(7,621) |
| Long-term incentive compensation | - | - | (2,353) | (2,353) |
| Amortization of reacquired franchise agreements | - | (1,806) | - | (1,806) |
| Excess tax benefits on stock compensation | - | - | 463 | 463 |
| Total | $- | $(1,806) | $(9,511) | $(11,317) |

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2026 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $52,207 | **$35,784** | **$(21,689)** | **$66,302** |
| **Add/(deduct):** |  |  |  |  |
| **Interest expense** | **50** | **136** | **326** | **512** |
| **Income taxes** | **16,528** | **11,028** | **(5,018)** | **22,538** |
| **Depreciation** | **5,912** | **8,379** | **12** | **14,303** |
| **Amortization** | **26** | **2,544** | **-** | **2,570** |
| **EBITDA** | **74,723** | **57,871** | **(26,369)** | **106,225** |
| **Add/(deduct):** |  |  |  |  |
| **Intercompany interest expense/(income)** | **(6,238)** | **(4,512)** | **10,750** | **-** |
| **Interest income** | **(95)** | **(15)** | **(779)** | **(889)** |
| **Stock option expense** | **-** | **-** | **9,249** | **9,249** |
| **Long-term incentive compensation** | **-** | **-** | **1,505** | **1,505** |
| **Acquisition expense** | **-** | **167** | **-** | **167** |
| **Adjusted EBITDA** | **$68,390** | **$53,511** | **$(5,644)** | **$116,257** |
|  |  |  |  | Chemed |
| For the three months ended March 31, 2025 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $50,030 | $39,944 | $(18,217) | $71,757 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 48 | 132 | 149 | 329 |
| Income taxes | 18,035 | 12,265 | (6,383) | 23,917 |
| Depreciation | 5,196 | 8,237 | 12 | 13,445 |
| Amortization | 26 | 2,546 | - | 2,572 |
| EBITDA | 73,335 | 63,124 | (24,439) | 112,020 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (5,296) | (3,930) | 9,226 | - |
| Interest income | (49) | (10) | (2,017) | (2,076) |
| Stock option expense | - | - | 9,091 | 9,091 |
| Long-term incentive compensation | - | - | 2,657 | 2,657 |
| Adjusted EBITDA | $67,990 | $59,184 | $(5,482) | $121,692 |

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| Net income as reported | **$66,302** | $71,757 |
| Add/(deduct) pre-tax cost of: |  |  |
| Stock option expense | **9,249** | 9,091 |
| Amortization of reacquired franchise agreements | **2,352** | 2,352 |
| Long-term incentive compensation | **1,505** | 2,657 |
| Acquisition expense | **167** | - |
| Add/(deduct) tax impacts: |  |  |
| Tax impact of the above pre-tax adjustments (1) | **(2,248)** | (2,320) |
| Excess tax expense/(benefit) on stock compensation | **56** | (463) |
| Adjusted net income | **$77,383** | $83,074 |
| Diluted Earnings Per Share As Reported |  |  |
| Net income | **$4.84** | $4.86 |
| Average number of shares outstanding | **13,690** | 14,764 |
| Adjusted Diluted Earnings Per Share |  |  |
| Adjusted net income | **$5.65** | $5.63 |
| Adjusted average number of shares outstanding | **13,690** | 14,764 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |  |  |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2026 | 2025 |
| --- | ---: | ---: |
| Homecare | **$371,091** | $351,566 |
| Inpatient | **35,925** | 34,022 |
| Continuous care | **18,133** | 24,637 |
| Other | **5,578** | 5,344 |
| Subtotal | **$430,727** | $415,569 |
| Room and board, net | **(3,257)** | (3,525) |
| Contractual allowances | **(5,077)** | (2,319) |
| Medicare cap allowance | **(2,375)** | (2,325) |
| Total | **$420,018** | $407,400 |
| Net revenue as a percent of total before Medicare cap allowances |  |  |
| Homecare | **86.2%** | 84.6% |
| Inpatient | **8.3** | 8.2 |
| Continuous care | **4.2** | 5.9 |
| Other | **1.3** | 1.3 |
| Subtotal | **100.0** | 100.0 |
| Room and board, net | **(0.8)** | (0.8) |
| Contractual allowances | **(1.1)** | (0.6) |
| Medicare cap allowance | **(0.6)** | (0.6) |
| Total | **97.5%** | 98.0% |
| Days of care |  |  |
| Homecare | **1,691,619** | 1,632,569 |
| Nursing home | **294,818** | 307,108 |
| Respite | **10,875** | 9,995 |
| Subtotal routine homecare and respite | **1,997,312** | 1,949,672 |
| Inpatient | **30,474** | 29,704 |
| Continuous care | **17,288** | 22,620 |
| Total | **2,045,074** | 2,001,996 |
| Number of days in relevant time period | **90** | 90 |
| Average daily census (days) |  |  |
| Homecare | **18,796** | 18,140 |
| Nursing home | **3,276** | 3,412 |
| Respite | **120** | 111 |
| Subtotal routine homecare and respite | **22,192** | 21,663 |
| Inpatient | **339** | 330 |
| Continuous care | **192** | 251 |
| Total | **22,723** | 22,244 |
| Total Admissions | **19,394** | 18,139 |
| Total Discharges | **18,537** | 17,875 |
| Average length of stay (days) | **102.7** | 118.7 |
| Median length of stay (days) | **15.0** | 16.0 |
| ADC by major diagnosis |  |  |
| Cerebro | **44.5%** | 44.7% |
| Neurological | **11.3** | 12.4 |
| Cancer | **9.6** | 9.6 |
| Cardio | **16.3** | 16.1 |
| Respiratory | **7.7** | 7.2 |
| Other | **10.6** | 10.0 |
| Total | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |
| Cerebro | **26.9%** | 28.4% |
| Neurological | **6.9** | 6.5 |
| Cancer | **23.5** | 24.6 |
| Cardio | **15.8** | 15.0 |
| Respiratory | **12.4** | 11.6 |
| Other | **14.5** | 13.9 |
| Total | **100.0%** | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | **1.2%** | 0.6% |
| Accounts receivable -- |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **38.8** | 47.3 |
| Days of revenue outstanding- including unapplied Medicare payments | **33.6** | 44.5 |

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

## Market risk

As filed, 572 characters.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2026, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

## Controls and procedures

As filed, 865 characters.

We carried out an evaluation, under the supervision of the Company’s President and Chief Executive Officer and with the participation of the Executive Vice President, Chief Financial Officer and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer and Executive Vice President, Chief Financial Officer and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 175 characters.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on form 10-Q.

Filed Apr 28, 2026.
Source: SEC EDGAR, the filing index for accession 0000019584-26-000012. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
